2.20 USD
↗ 0.02 (0.92%)AT CLOSE (11:59 AM EDT)
Grace Therapeutics, Inc. Common Stock
GRCENASDAQ • USD
2.23
↗ 0.03 (1.36%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
2.23
↗ 0.03 (1.36%)
Market: OPEN
Shares of Grace Therapeutics, Inc. Common Stock (GRCE) are trading at $2.23. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, GRCE appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Aug 25, 2026.
Open?$2.18
High?$2.22
Low?$2.18
Prev. Close?$2.18
Volume?94.4K
Avg. Volume?212.5K
VWAP?$2.20
Rel. Volume?0.44x
Bid / Ask
Bid?$1.87 × 100
Ask?$2.50 × 100
Spread?$0.63
Midpoint?$2.19
Valuation & Ratios
Market Cap?45.9M
Shares Out?21.0M
Float?15.1M
Float %?71.6%
P/E Ratio?N/A
P/B Ratio?0.95
EPS?-$0.96
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Address
103 CARNEGIE CENTER
PRINCETON, NJ 08540
Phone: 609-322-1602
PRINCETON, NJ 08540
Phone: 609-322-1602
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?54
Piotroski F-Score?0/9Weak
Altman Z-Score?6.69Safe
Confidence?36%Very Low
Short InterestHigh
Short % of Float?10.78%High
Short Interest?1.6M
Days to Cover?7.9
Free Float15.1M
Avg Daily Volume205.0K
Settlement Date2026-08-14
Financial Health
Current Ratio?11.47Strong
Quick Ratio?11.47Strong
Cash Ratio?11.00Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.95CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.1CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-41.9%WEAK▾
S&P3
ROA?-40.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-10289000
Enterprise Value?$32.1M
Fundamentals ratios updated end of day